The Board of Directors in its meeting held on Friday, 14th November, 2025 at 4:00 p.m. have considered and approved the following: 1. Un-Audited Financial Results for the quarter and ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts more than Nifty Microcap 250 and 3.4 pts more than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved unaudited financial results for the quarter and half year ended 30 September 2025 on 14 November 2025. Revenue from operations surged to ₹1,037 lakh in Q2 FY26 (up from ₹632 lakh in Q1) and ₹1,669 lakh for H1 FY26, compared to zero revenue in the corresponding prior-year periods, indicating a sharp restart of business activity. Despite the revenue pickup, the company slipped further into losses with a Q2 net loss of ₹24 lakh and an H1 net loss of ₹58 lakh, though this is narrower than the H1 FY25 loss of ₹91 lakh. Other equity remains deeply negative at ₹(5,903) lakh against share capital of ₹7,485 lakh, reflecting accumulated losses, while total equity stands at ₹1,582 lakh. Borrowings are ₹774 lakh and cash equivalents are minimal at ₹5 lakh. The limited review report by A. Sachdev & Co. is clean with no qualifications or emphasis-of-matter paragraphs.
Shareholders should note this is a loss-making small-cap with negative reserves, where the revenue restart is a positive sign but profitability remains elusive and balance sheet is stretched with thin cash buffers. The stock may remain volatile and speculative until the company demonstrates sustained profits and improves its equity position.